ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 561

Acyl-CoA Synthetase 1 Expression Is Increased In Murine Models Of Lupus As Well As In Human Systemic Lupus Erythematosus

Eyal Kedar1, Shelley Barnhart2, Keith B. Elkon3 and Karin Bornfeldt2, 1Rheumatology, University of Washington, Seattle, WA, 2Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA, 3Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Lupus

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: The enzyme acyl-CoA synthetase 1 (ACSL1) converts free fatty acids into their biologically active acyl-CoA derivatives. It is induced by lipopolysaccharide and cytokines (including IFN-gamma and TNF-alpha) and is detected in macrophages in type 1 diabetes mellitus. Increased expression is associated with the inflammatory activation of these cells. ACSL1 promotes membrane phospholipid turnover in activated macrophages, which might contribute to its inflammatory effects. This study was conducted to investigate whether ACSL1 is upregulated in myeloid cells in both human and mouse lupus.

Methods: Acsl1 mRNA levels were measured in human peripheral blood mononuclear cells of patients with lupus and controls, and in splenocytes of TLR7 transgenic mice. Bone marrow-derived macrophages and thioglycollate-elicited peritoneal macrophages from C57/B6 mice were also stimulated with universal type 1 interferon (5, 50 and 500 U/mL), and Acsl1 mRNA and protein levels were measured. Finally, C57/B6 mice were injected i.p. with 0.5 mL of pristane, and blood monocytes and bone marrow monocytes were isolated by negative magnetic bead selection two weeks later. Messenger RNA levels of Acsl1 as well as three lupus interferon signature genes (Isg15, Irf7 and Cxcl10) were determined by  real-time PCR.

Results: ACSL1 mRNA expression was increased in peripheral blood mononuclear cells of patients with lupus (p=0.004) as compared to matched controls. Expression was also increased in splenocytes obtained from the TLR7 transgenic mouse model of lupus (p<0.05). Since Acsl1 expression was increased in both mouse and human lupus, we asked whether Acsl1 could be an interferon-stimulated gene (ISG). We observed that Acsl1 mRNA was induced 3-4 fold by type 1 IFN in thioglycollate-elicited macrophages (p<0.05) and was induced 6-7 fold in bone marrow-derived macrophages (p=0.005), concomitant with an increase in the well-known ISG Cxcl10.  Acsl1 protein was also increased following interferon stimulation. We observed that Acsl1 was induced by pristane in bone marrow monocytes (p=0.03), and was positively associated with the rise of the three lupus interferon signature genes in blood monocytes (p<0.05).  

Conclusion: This is the first demonstration of increased expression of Acsl1 in human lupus as well as in mouse models of this disease. These findings demonstrate that ACSL1 is an ISG. The functional significance of these observations are that type 1 IFN’s may drive expression of Acsl1 in lupus, which in turn, given ACSL1’s ability to promote membrane phospholipid turnover, may modulate the inflammatory potential of monocytes or macrophages in this disease. The direct variation of Acsl1 with the three lupus interferon signature genes we studied further suggests a potential signaling role of ACSL1 and/or its downstream metabolites in either the TLR7 or IFN receptor (IFNAR) signaling pathways in lupus.


Disclosure:

E. Kedar,
None;

S. Barnhart,
None;

K. B. Elkon,
None;

K. Bornfeldt,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acyl-coa-synthetase-1-expression-is-increased-in-murine-models-of-lupus-as-well-as-in-human-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology